U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H13NO4
Molecular Weight 247.2466
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CX614

SMILES

O=C1N2CCCC2OC3=CC4=C(OCCO4)C=C13

InChI

InChIKey=RQEPVMAYUINZRE-UHFFFAOYSA-N
InChI=1S/C13H13NO4/c15-13-8-6-10-11(17-5-4-16-10)7-9(8)18-12-2-1-3-14(12)13/h6-7,12H,1-5H2

HIDE SMILES / InChI

Description

CX614 (2H,3H,6aH-pyrrolidino(2,1-3',2')1,3-oxazino(6',5'-5,4)benzo(e)1,4-dioxan-10-one) is a positive allosteric modulator of the AMPA receptor. Chronic treatment of rat hippocampal slices with CX614 gradually reduced levels of glutamate receptor (GluR)1 and GluR2/3 AMPA subunits and of their anchoring proteins synapse-associated protein 97 (SAP97) and glutamate receptor interacting protein 1 (GRIP1). The physiological and toxicological properties of this compound have not been evaluated in humans.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
21.0 µM [EC50]
46.0 µM [EC50]
71.0 µM [EC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Outside-out membrane patches from transfected HEK293 cells were held under voltage-clamp at a holding potential of _60 mV using an Axopatch 200B amplifier. During recordings, cells were perfused continuously with extracellular control solution containing 20 mM sucrose, 145 mM NaCl, 5.4 mM KCl, 5 mM HEPES, 1 mM MgCl2, 1.8 mM CaCl2, and 0.01 mg/ml phenol red, pH 7.3. Currents were evoked with test solutions containing 10 mM glutamate. Control and test solutions were perfused through quartz tubing. The patch pipette tip was positioned in the control solution stream near the interface between the control and glutamate-containing streams. When modulators were used, they were added to both test and control solutions in the following concentrations: 100 mkM CTZ, 100 mkM CX614, and 10 mkM CMPDA or CMPDB. Modulator stock solutions (10 mM) were dissolved in DMSO before dilution in extracellular solutions; final DMSO concentrations were 0.3 to 1%. When applying glutamate in the absence of modulator, after having perfused modulator through the tubing for a previous patch, we noticed that the steady-state current responses were not completely desensitized.